| Execution period | FY 2026-27 |
|---|
NSE filing, NSE: VALIANTLAB. Summary written from the filing by ALFA Finder's alert engine.
Valiant Laboratories Ltd: key numbers
- Share price
- ₹125.82
- Market cap
- ₹683.4 Cr
- Revenue (annual)
- ₹237.5 Cr
- Net profit (annual)
- ₹-3.27 Cr
- P/E (TTM)
- 42.7×Sector 46.1×
- Promoter holding
- 74.94%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Valiant Laboratories Ltd
All →Valiant Laboratories Board Meeting Date
Valiant Laboratories will meet on 2 November 2026 to approve half-year audited results. The trading window stays closed until 4 November.
Valiant Laboratories Other Announcement
Valiant Laboratories Ltd has filed its shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
Valiant Laboratories Annual General Meeting
Valiant Laboratories Limited successfully conducted its 5th Annual General Meeting on September 28, 2026, transacting 18 agenda items including financial statements and various re-appointments.
Valiant Laboratories Acquisition Worth ₹0.7 Cr
Valiant Laboratories approved acquiring up to 1.01% equity in AMPYR Renewable Energy for ₹0.70 Crore. The investment enables captive solar power for its Tarapur plant.
- Value
- ₹0.70 Cr
- Execution
- 12 months from date of board approval
Valiant Laboratories Credit Rating
Valiant Laboratories Limited received a credit rating of IND BBB/Stable/IND A2 from India Ratings and Research for bank loan facilities totaling INR 56 Crore.
- Value
- ₹56.00 Cr
Valiant Laboratories Other Announcement
Valiant Laboratories Limited has dispatched letters to shareholders who have not registered their email addresses, providing access to the Annual Report and 5th AGM notice.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.